Skip to content

Evaluation for the efficiency and safety of tranexamic acid in pelvic fracture operation

Evaluation for the efficiency and safety of tranexamic acid in pelvic fracture operation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-ICC-15006070
Enrollment
Unknown
Registered
2015-03-13
Start date
2015-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

trauma

Interventions

TXA group:Intravenous administration of the tranexamic acid (10mg/Kg) before surgery
Control group:Intravenous administration 0.9%NS before surgery

Sponsors

The Military General Hospital of Chengdu, PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: The patients suffer from pelvic fracture who need to undergo internal fixation operation; between 18-70 years old;patient informed consent.

Exclusion criteria

Exclusion criteria: allergy to TXA; hemoglobin <90g/L (female) or <100g/L (male); platelets<150000 mm3; coagulation dysfunction; receiving antiplatelet or anticoagulant therapy; thrombosis embolism history; hypercoagulable state; renal dysfunction; hepatic insufficiency.

Design outcomes

Primary

MeasureTime frame
The volume of blood loss during operation;The volume of drainage postoperative;The volume of blood transfusion;Hemoglobin;

Secondary

MeasureTime frame
Fibrinogen;D- dimer;INR;PT;APTT;

Countries

China

Contacts

Public ContactLiao Dongfa
449250924@qq.com+86 13980733272

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026